In accordance with section 27a of Consolidated Act about Securities Trading etc., we hereby issue a complete list of NeuroSearch announcements in 2008 and in January - March 2009. All announcements are available under the IR section of our homepage www.neurosearch.com. Date / No. / Heading 04.01.2008 01-08 NeuroSearch announces the end of stabilisation period in connection with the rights issue, completed November 2007 17.01.2008 02-08 NeuroSearch issues 185,755 new shares to the sellers of Carlsson Research AB as milestone payment relating to the start of ACR343 Phase I study 22.01.2008 03-08 NeuroSearch announces revised financial calendar for 2008 23.01.2008 04-08 NeuroSearch has issued 185,755 new shares in a directed issuance to the sellers of Carlsson Research AB 31.01.2008 05-08 NeuroSearch A/S' share capital and voting rights 03.03.2008 06-08 NeuroSearch publishes positive and confirmatory results from TIPO-2, a clinical metabolic study with tesofensine for the treatment of obesity 04.03.2008 07-08 NeuroSearch A/S - Financial statements 2007 06.03.2008 08-08 List of NeuroSearch announcements in 2007 and in January - March 2008 11.03.2008 09-08 NeuroSearch issues new shares in connection with exercise of warrants 31.03.2008 10-08 NeuroSearch initiates clinical Phase I study with NSD-788 for the treatment of anxiety and depression 31.03.2008 11-08 NeuroSearch A/S' share capital and voting rights 15.04.2008 12-08 Changes in the board of directors of NeuroSearch A/S 15.04.2008 13-08 Notice convening ordinary general meeting in NeuroSearch 25.04.2008 14-08 NeuroSearch initiates pivotal Phase III programme with ACR16 for the treatment of Huntington's disease 28.05.2008 15-08 Notice concerning proxies received for the Annual General Meeting of NeuroSearch A/S 30.04.2008 16-08 NeuroSearch A/S - Q1 Report 2008 30.04.2008 17-06 Report on ordinary general meeting held in NeuroSearch A/S 05.05.2008 18-08 Notice convening Extraordinary General Meeting in NeuroSearch A/S 21.05.2008 19-08 NeuroSearch has decided to issue 300,000 new shares in a directed offering subscribed for by institutional investors at a price of DKK 280 per share to finance a milestone payment to the sellers of Carlsson Research AB 21.05.2008 20-08 NeuroSearch releases time schedule for the completion of the directed offering of 300,000 new shares subscribed for by institutional investors to finance a milestone payment to the sellers of Carlsson Research AB 21.05.2008 21-08 The shareholdings of A.J. Aamund in NeuroSearch is diluted to less than 5% in connection with the company's issue of 300,000 new shares 23.05.2008 22-08 Report on extraordinary general meeting held in NeuroSearch A/S 26.05.2008 23-08 NeuroSearch has issued 300,000 new shares in a directed offering subscribed for by institutional investors to finance a milestone payment related to the initiation of a Phase III study with ACR16 in Huntington's disease 30.05.2008 24-08 NeuroSearch A/S' share capital and voting rights 20.06.2008 25-08 NeuroSearch announces positive key results from a Phase II study with ABT-894 in adults with Attention Deficit-Hyperactivity Disorder (ADHD) 26.06.2008 26-08 NeuroSearch successfully completes Phase I with ACR325 and announces the decision to progress development into Phase II Proof-of-Concept studies in Parkinson's disease and Bipolar Disorder 08.07.2008 27-08 NeuroSearch's TIPO-4 study with tesofensine confirms the efficacy in weight management previously reported in TIPO-1 and provides the first long-term data with an average weight loss of 13 to 14 kg 10.07.2008 28-08 NeuroSearch receives an IND approval from the FDA for ACR16 as part of an ongoing pivotal clinical programme in Huntington's disease 11.08.2008 29-08 NeuroSearch reports final results from the TIPO-2 study with tesofensine in obesity 27.08.2008 30-08 NeuroSearch announces revised financial calendar for 2008 27.08.2008 31-08 NeuroSearch A/S - Interim report for the first half-year of 2008 09.09.2008 32-08 NeuroSearch issues new shares in connection with exercise of warrants 30.09.2008 33-08 NeuroSearch A/S' share capital and voting rights 27.10.2008 34-08 NeuroSearch announces the dosing of the first patients in the US HART study, a part of the ongoing ACR16 pivotal programme in Huntington's disease 17.11.2008 35-08 NeuroSearch A/S - Q3 report 2008 26.11.2008 36-08 NeuroSearch announces highly positive and supportive final results from a cardiovascular safety evaluation study with the anti-obesity drug tesofensine 23.12.2008 37-08 NeuroSearch announces financial calendar for 2009 29.01.2009 01-09 NeuroSearch announce an expansion to their existing alliance with GlaxoSmithKline 11.02.2009 02-09 NeuroSearch announces results from Phase II studies of ABT-894 in diabetic neuropathic pain 17.02.2009 03-09 NeuroSearch announces drug discovery and development alliance with Eli Lilly and Company 23.02.2009 04-09 NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression 02.03.2009 05-09 NeuroSearch regains global rights to ACR16 03.03.2009 06-09 NeuroSearch has issued 530,745 new shares in a directed offering subscribed by Eli Lilly and Company in connection with the signing of a drug discovery and development alliance 04.03.2009 07-09 NeuroSearch A/S Financial Statements 2008 Flemming Pedersen CEO Contact person: Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of NeuroSearch's activities is partner financed through an alliance with Eli Lilly and Company and collaborations with GlaxoSmithKline (GSK) and Abbott. The drug pipeline comprises 8 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's disease (Phase II ready), ABT-107 and ABT-560 for the treatment of various CNS disorders - both (Phase I) in collaboration with Abbott, ACR343 for schizophrenia (Phase II ready) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
List of NeuroSearch announcements in 2008 and in January - March 2009
| Source: NTG Nordic Transport Group A/S